Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 1665-1669

  Mar Rodriguez M ^a   Javier Pastor, F ^a   Sutton, Deanna A ^b   Calvo, Enrique ^a   Fothergill, Annette W ^b   Salas, Valentina ^a   Rinaldi, Michael G ^b   Guarro, Josep ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; POSACONAZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BACTERIAL INFECTION; BODY WEIGHT; BRAIN; BROTH DILUTION; CONTROLLED STUDY; DIFFUSION; DRUG EFFICACY; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; RHIZOPUS ORYZAE; SURVIVAL RATE; TABLET DIFFUSION;

ANIMALS; ANTIFUNGAL AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, FUNGAL; KAPLAN-MEIERS ESTIMATE; KIDNEY; MICE; MUCORMYCOSIS; RHIZOPUS; TRIAZOLES;

EID: 77951248570     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01463-09     Document Type: Article

References (22)

1. Almyroudis, N. G., D. A. Sutton, A. W. Fothergill, M. G. Rinaldi, and S. Kusne. 2007. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob. Agents Chemother. 51:2587-2590.
2. Alvarez, E., D. A. Sutton, J. Cano, A. W. Fothergill, A. Stchigel, M. G. Rinaldi, and J. Guarro. 2009. Spectrum of zygomycete species identified in clinically significant specimens in the United States. J. Clin. Microbiol. 47:1650-1656.
3. Barchiesi, F., E. Spreghini, A. Santinelli, A. W. Fothergill, E. Pisa, D. Giannini, M. G. Rinaldi, and G. Scalise. 2007. Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob. Agents Chemother. 51:73-77.
4. Dannaoui, E., J. F. G. M. Meis, D. Loebenberg, and P. E. Verweij. 2003. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob. Agents Chemother. 47:3647-3650.
5. Espinel-Ingroff, A., B. Arthington-Skaggs, N. Iqbal, D. Ellis, M. A. Pfaller, S. Messer, M. Rinaldi, A. Fothergill, D. L. Gibbs, and A. Wang. 2007. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin. J. Clin. Microbiol. 45:1811-1820.
6. Espinel-Ingroff, A., and E. Canton. 2008. Comparison of Neo-Sensitabs tablet diffusion assay with CLSI broth microdilution M38-A and disk diffusion methods for testing susceptibility of filamentous fungi with amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole. J. Clin. Microbiol. 46:1793-1803.
7. Espinel-Ingroff, A., V. Chaturvedi, A. Fothergill, and M. G. Rinaldi. 2002. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J. Clin. Microbiol. 40:3776-3781.
8. Greenberg, R. N., K. Mullane, J. A. van Burik, I. Raad, M. J. Abzug, G. Anstead, R. Herbrecht, A. Langston, K. A. Marr, G. Schiller, M. Schuster, J. R. Wingard, C. E. Gonzalez, S. G. Revankar, G. Corcoran, R. J. Kryscio, and R. Hare. 2006. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. 50:126-133.
9. Ibrahim, A. S., T. Gebremariam, J. A. Schwartz, J. E. Edwards, Jr., and B. Spellberg. 2009. Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob. Agents Chemother. 53:772-775.
10. Krishna, G., M. Martinho, P. Chandrasekar, A. J. Ullman, and H. Patino. 2007. Pharmacokinetics of oral posaconazole in allogenic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27:1627-1636.
11. Krishna, G., A. Sansone-Parsons, M. Martinho, B. Kantesaria, and L. Pedicone. 2007. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob. Agents Chemother. 51:812-818.
12. Lass-Flörl, C., A. Mayr, S. Perkhofer, G. Hintenberger, J. Hausdorfer, C. Speth, and M. Fille. 2008. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 52:3637-3641.
13. National Committee for Clinical Laboratory Standards/Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard, 2nd ed. Document M38-A2. National Committee for Clinical Laboratory Standards/ Clinical and Laboratory Standards Institute, Wayne, PA.
14. Nguyen, M. H., C. J. Clancy, V. L. Yu, Y. C. Yu, A. J. Morris, D. R. Snydman, D. A. Sutton, and M. G. Rinaldi. 1998. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J. Infect. Dis. 177:425-430.
15. Ortoneda, M., J. Capilla, F. J. Pastor, C. Serena, and J. Guarro. 2004. Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis. Diagn. Microbiol. Infect. Dis. 50:247-251.
16. Pfaller, M. A., S. A. Messer, R. J. Hollis, and R. N. Jones. 2002. Antifungal activities of posaconazole, ravuconazole, and voriconazole, compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother. 46: 1032-1037.
17. Rex, J., M. Pfaller, T. Walsh, V. Chaturvedi, A. Espinel-Ingroff, M. Ghannoum, L. Gosey, F. C. Odds, M. Rinaldi, D. Sheehan, and D. Warnock. 2001. Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbiol. Rev. 14:643-658.
18. Rodríguez, M. M., F. J. Pastor, E. Calvo, V. Salas, D. A. Sutton, and J. Guarro. 2009. Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrob. Agents Chemother. 53:5022-5025.
19. Rodríguez, M. M., C. Serena, M. Mariné, F. J. Pastor, and J. Guarro. 2008. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob. Agents Chemother. 52:3786-3788.
20. Rogers, T. R. 2008. Treatment of zygomycosis: current and new options. J. Antimicrob. Chemother. 61:35-39.
21. Spellberg, B., T. J. Walsh, D. P. Kontoyiannis, J. E. Edwards, Jr., and A. S. Ibrahim. 2009. Recent advances in the management of mucormycosis: from bench to bedside. Clin. Infect. Dis. 48:1743-1751.
22. van Burik, J. A. H., R. S. Hare, H. F. Solomon, M. L. Corrado, and D. P. Kontoyiannis. 2006. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42:61-65.